HRT for Perimenopause
You do not have to wait until menopause to get help. Hormone therapy during perimenopause addresses the hormonal volatility driving your symptoms now, with approaches tailored to where you are in the transition.
why HRT now
Why Hormone Therapy Works During Perimenopause
Perimenopause is defined by hormonal instability, not just hormonal decline. Estrogen and progesterone levels swing unpredictably, sometimes producing surges that mimic early pregnancy symptoms followed by drops that trigger hot flashes, anxiety, and sleep collapse. This volatility is what makes perimenopause symptoms so disruptive and so difficult for many providers to treat effectively.
Hormone therapy during perimenopause stabilizes the fluctuations. Rather than waiting for hormones to bottom out entirely (menopause), treatment introduced during the transition smooths the hormonal curve, reducing symptom intensity and improving quality of life during the years that are often the most disruptive.
The approach differs from standard menopause HRT. In early perimenopause, progesterone therapy alone may be sufficient. As the transition progresses and estrogen levels decline more consistently, low-dose estrogen is added. This staged, responsive approach is a hallmark of physician-guided care.
An important note
HRT during perimenopause does not function as contraception. Women who could still become pregnant should discuss contraceptive needs with their provider separately.
treatment approaches
Perimenopause HRT Approaches at Eros MD
The approach to HRT during perimenopause is staged. In early perimenopause, when cycles are still occurring but becoming irregular and the primary symptoms are sleep disruption, anxiety, and mood changes, oral micronized progesterone alone is often sufficient. As the transition progresses and estrogen levels decline more consistently, low-dose transdermal estradiol is added. The protocol evolves as your physiology changes.
Important Note
Perimenopausal hormone patterns fluctuate erratically, not smoothly. Labs drawn in isolation often look 'normal.' Treatment is primarily symptom-driven, with labs providing context when clinically unclear. Your provider adjusts protocols as your transition progresses.
Stage 1: Progesterone-First
Early perimenopause. Cycles still occurring but becoming irregular. Primary symptoms are sleep disruption, anxiety, and mood changes. Oral micronized progesterone, taken cyclically or nightly. Restores sleep, calms anxiety, regulates bleeding.
Stage 2: Estrogen + Progesterone
Mid-to-late perimenopause. Cycles becoming infrequent. Hot flashes, night sweats, and cognitive symptoms emerging. Low-dose transdermal estradiol added to micronized progesterone. Dose lower than standard menopause HRT, adjusted to symptom response.
Adjusted Over Time
Your protocol evolves as your transition progresses. Reassessment every 3 to 6 months. Transition seamlessly into standard menopause HRT when appropriate.
why progesterone first
Stage 1: Progesterone-First Therapy in Early Perimenopause
Progesterone is the first hormone to decline in perimenopause and is often sufficient to address the earliest symptom cluster. Oral micronized progesterone, typically taken cyclically (days 12 to 26 of cycle) or nightly, restores sleep architecture, calms GABA pathways (reducing anxiety), and regulates menstrual bleeding. It does not suppress ovulation, meaning it does not function as contraception. As the transition progresses and vasomotor symptoms emerge, transdermal estradiol is added at low dose, with cycle pattern and symptom response guiding the dose.
the fine print
Perimenopause HRT Side Effects and Safety Information
Common Side Effects
Morning drowsiness from oral progesterone (typically welcome given sleep improvement)
Breast tenderness (usually resolves in 4 to 8 weeks)
Vaginal spotting early in therapy
Mild mood fluctuations as hormones stabilize
Side effects typically improve within the first 2 to 3 months
Serious Considerations
Standard HRT contraindications apply: personal history of breast cancer, VTE, estrogen-sensitive cancers, active liver disease. Progesterone alone has a more favorable safety profile than combined HRT. Cyclic protocols for women still cycling require different counseling around period patterns. HRT does not provide contraception. Your Eros MD provider screens for all of these.
Eros MD Safety Process
Review includes menstrual history, symptom pattern, family history of breast and estrogen-sensitive cancers and VTE, and current medications. Protocol is staged based on where you are in the transition. Follow-up at 3 months to assess response and transition to the next phase as needed.
How it works
How to Start Perimenopause HRT Through Eros MD
Flexible, staged protocol design, matched to where you are in the transition.
Complete your confidential intake covering symptoms, cycle history, health conditions, and goals.
Physician orders appropriate labs and reviews your full clinical picture.
Discussion of findings, diagnosis, and staged treatment plan.
Prescription and delivery. Ongoing monitoring as your transition progresses.
Questions worth asking
Frequently Asked Questions About Perimenopause HRT
If you are experiencing perimenopause symptoms confirmed by clinical evaluation, you are not too young for treatment. HRT can be safely initiated during perimenopause. In fact, early intervention often produces better symptom control and may support long-term health outcomes.
Not necessarily. Some women use perimenopause HRT for several years during the transition and then taper off. Others transition seamlessly into standard menopause HRT. Duration is individualized and reassessed regularly with your provider.
Yes. In early perimenopause, progesterone-only therapy is often the first-line approach and may be sufficient to address sleep disruption, anxiety, and menstrual irregularity. Estrogen is added later if symptoms progress.
HRT can regulate irregular perimenopausal bleeding, often making cycles more predictable. Your provider monitors your response and adjusts the approach as your transition progresses.